Published in Proc Natl Acad Sci U S A on April 25, 2011
Sequenced Treatment Alternatives to Relieve Depression (STAR*D) | NCT00021528
A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry (2013) 2.68
From stress to inflammation and major depressive disorder: a social signal transduction theory of depression. Psychol Bull (2014) 2.39
How might circadian rhythms control mood? Let me count the ways... Biol Psychiatry (2013) 1.95
Antidepressant response in patients with major depression exposed to NSAIDs: a pharmacovigilance study. Am J Psychiatry (2012) 1.57
Identification of host-targeted small molecules that restrict intracellular Mycobacterium tuberculosis growth. PLoS Pathog (2014) 1.51
Cytokine targets in the brain: impact on neurotransmitters and neurocircuits. Depress Anxiety (2013) 1.48
The inflammasome: pathways linking psychological stress, depression, and systemic illnesses. Brain Behav Immun (2012) 1.42
Neuroinflammation and psychiatric illness. J Neuroinflammation (2013) 1.42
Identification of the cortical neurons that mediate antidepressant responses. Cell (2012) 1.42
Cholinergic interneurons in the nucleus accumbens regulate depression-like behavior. Proc Natl Acad Sci U S A (2012) 1.33
The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat Rev Immunol (2015) 1.28
Dynamic microglial alterations underlie stress-induced depressive-like behavior and suppressed neurogenesis. Mol Psychiatry (2013) 1.26
Exaggerated neurobiological sensitivity to threat as a mechanism linking anxiety with increased risk for diseases of aging. Neurosci Biobehav Rev (2012) 1.22
A dialogue between the immune system and brain, spoken in the language of serotonin. ACS Chem Neurosci (2012) 1.20
Depression and serotonin reuptake inhibitor treatment as risk factors for preterm birth. Epidemiology (2012) 1.18
Responder and nonresponder patients exhibit different peripheral transcriptional signatures during major depressive episode. Transl Psychiatry (2012) 1.08
p11 and its role in depression and therapeutic responses to antidepressants. Nat Rev Neurosci (2013) 1.07
Neuroimmune mechanisms of depression. Nat Neurosci (2015) 1.05
The annexin A2/S100A10 system in health and disease: emerging paradigms. J Biomed Biotechnol (2012) 0.96
Treating depression and depression-like behavior with physical activity: an immune perspective. Front Psychiatry (2013) 0.95
Serum S100B represents a new biomarker for mood disorders. Curr Drug Targets (2013) 0.94
Mechanisms of antidepressant resistance. Front Pharmacol (2013) 0.92
Annexin A2 system in human biology: cell surface and beyond. Semin Thromb Hemost (2013) 0.92
Inflammasomes: molecular regulation and implications for metabolic and cognitive diseases. Mol Cells (2014) 0.90
Malaise, melancholia and madness: the evolutionary legacy of an inflammatory bias. Brain Behav Immun (2013) 0.89
Toll-like receptor 4: innate immune regulator of neuroimmune and neuroendocrine interactions in stress and major depressive disorder. Front Neurosci (2014) 0.88
Inflammation in neurological and psychiatric diseases. Inflammopharmacology (2012) 0.87
Acute psychological stress results in the rapid development of insulin resistance. J Endocrinol (2013) 0.86
A novel role for brain interleukin-6: facilitation of cognitive flexibility in rat orbitofrontal cortex. J Neurosci (2014) 0.86
Early responses to deep brain stimulation in depression are modulated by anti-inflammatory drugs. Mol Psychiatry (2013) 0.85
Therapeutic Implications of Brain-Immune Interactions: Treatment in Translation. Neuropsychopharmacology (2016) 0.85
Alteration by p11 of mGluR5 localization regulates depression-like behaviors. Mol Psychiatry (2015) 0.84
Do cytokines really sing the blues? Cerebrum (2013) 0.84
Minocycline as an adjunct for treatment-resistant depressive symptoms: study protocol for a pilot randomised controlled trial. Trials (2015) 0.83
Inflammation in Depression and the Potential for Anti-Inflammatory Treatment. Curr Neuropharmacol (2016) 0.83
Pathogenesis of depression: Insights from human and rodent studies. Neuroscience (2015) 0.82
Inflammation as a predictive biomarker for response to omega-3 fatty acids in major depressive disorder: a proof-of-concept study. Mol Psychiatry (2015) 0.82
Somatic drugs for psychiatric diseases: aspirin or simvastatin for depression? Curr Neuropharmacol (2012) 0.81
Immune and Neuroendocrine Mechanisms of Stress Vulnerability and Resilience. Neuropsychopharmacology (2016) 0.80
Anhedonic behavior in cryptochrome 2-deficient mice is paralleled by altered diurnal patterns of amygdala gene expression. Amino Acids (2015) 0.80
Parallels between major depressive disorder and Alzheimer's disease: role of oxidative stress and genetic vulnerability. Cell Mol Neurobiol (2014) 0.79
Immune and neurotrophin stimulation by electroconvulsive therapy: is some inflammation needed after all? Transl Psychiatry (2015) 0.79
N-Desmethylclozapine, Fluoxetine and Salmeterol inhibit post-entry stages of dengue virus life-cycle. Antimicrob Agents Chemother (2016) 0.79
Inflammation and depression: combined use of selective serotonin reuptake inhibitors and NSAIDs or paracetamol and psychiatric outcomes. Brain Behav (2015) 0.78
Annual research review: The neuroinflammation hypothesis for stress and psychopathology in children--developmental psychoneuroimmunology. J Child Psychol Psychiatry (2013) 0.78
Aspirin and multiple sclerosis. BMC Med (2015) 0.78
Neuroimmunomodulation in unipolar depression: a focus on chronobiology and chronotherapeutics. J Neural Transm (Vienna) (2012) 0.78
Stress-induced neuroinflammation is mediated by GSK3-dependent TLR4 signaling that promotes susceptibility to depression-like behavior. Brain Behav Immun (2016) 0.77
Serotonin, cytokines, p11, and depression. Proc Natl Acad Sci U S A (2011) 0.77
Are antidepressants effective in the acute and long-term treatment of depression? Sic et Non. Innov Clin Neurosci (2012) 0.77
Anti-inflammatory drugs as moderators of antidepressant effects, especially those of the selective serotonin-reuptake inhibitor class. Expert Rev Clin Pharmacol (2011) 0.77
Plant Natural Product Puerarin Ameliorates Depressive Behaviors and Chronic Pain in Mice with Spared Nerve Injury (SNI). Mol Neurobiol (2016) 0.77
Taking the Perspective that a Depressive State Reflects Inflammation: Implications for the Use of Antidepressants. Front Psychol (2012) 0.76
Molecular serum signature of treatment resistant depression. Psychopharmacology (Berl) (2016) 0.76
Monitoring candidate gene expression variations before, during and after a first major depressive episode in a 51-year-old man. BMC Psychiatry (2014) 0.76
Cell- and region-specific expression of depression-related protein p11 (S100a10) in the brain. J Comp Neurol (2016) 0.75
Alteration of immune markers in a group of melancholic depressed patients and their response to electroconvulsive therapy. J Affect Disord (2016) 0.75
Inflammation and Immune Regulation as Potential Drug Targets in Antidepressant Treatment. Curr Neuropharmacol (2016) 0.75
Essential Contributions of Serotonin Transporter Inhibition to the Acute and Chronic Actions of Fluoxetine and Citalopram in the SERT Met172 Mouse. Neuropsychopharmacology (2015) 0.75
Neuroinflammation and cytokine abnormality in major depression: Cause or consequence in that illness? World J Psychiatry (2016) 0.75
Maternal Pharmacokinetics and Fetal Disposition of (±)-Citalopram during Mouse Pregnancy. ACS Chem Neurosci (2016) 0.75
Cellular and molecular basis for stress-induced depression. Mol Psychiatry (2016) 0.75
Systematic review of interventions for depression and anxiety in persons with inflammatory bowel disease. BMC Res Notes (2016) 0.75
Neuron-Microglia Interactions in Mental Health Disorders: "For Better, and For Worse". Front Immunol (2016) 0.75
Microglia in the dorsal raphe nucleus plays a potential role in both suicide facilitation and prevention in affective disorders. Eur Arch Psychiatry Clin Neurosci (2017) 0.75
Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry (2006) 12.41
Deep brain stimulation for treatment-resistant depression. Neuron (2005) 12.39
Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry (2009) 8.74
The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice. Neurosci Biobehav Rev (2005) 4.64
Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assay. Clin Diagn Lab Immunol (2003) 3.76
Alterations in 5-HT1B receptor function by p11 in depression-like states. Science (2006) 3.55
Assessing substrates underlying the behavioral effects of antidepressants using the modified rat forced swimming test. Neurosci Biobehav Rev (2005) 3.32
Hippocampal neurogenesis: opposing effects of stress and antidepressant treatment. Hippocampus (2006) 3.02
Depressive disorders and immunity: 20 years of progress and discovery. Brain Behav Immun (2007) 2.75
The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry (2006) 2.44
Interferon-gamma and tumor necrosis factor-alpha mediate the upregulation of indoleamine 2,3-dioxygenase and the induction of depressive-like behavior in mice in response to bacillus Calmette-Guerin. J Neurosci (2009) 2.22
Reversal of depressed behaviors in mice by p11 gene therapy in the nucleus accumbens. Sci Transl Med (2010) 2.09
The STAR*D Project results: a comprehensive review of findings. Curr Psychiatry Rep (2007) 2.08
A CamKIIalpha iCre BAC allows brain-specific gene inactivation. Genesis (2001) 2.08
Cytokines as mediators of depression: what can we learn from animal studies? Neurosci Biobehav Rev (2005) 1.89
Up-regulation of BDNF in astrocytes by TNF-alpha: a case for the neuroprotective role of cytokine. J Neuroimmune Pharmacol (2006) 1.77
Role of p11 in cellular and behavioral effects of 5-HT4 receptor stimulation. J Neurosci (2009) 1.62
IFN-gamma enhances neurogenesis in wild-type mice and in a mouse model of Alzheimer's disease. FASEB J (2008) 1.34
A potential role for pro-inflammatory cytokines in regulating synaptic plasticity in major depressive disorder. Int J Neuropsychopharmacol (2009) 1.28
Interferon gamma induces neurite outgrowth by up-regulation of p35 neuron-specific cyclin-dependent kinase 5 activator via activation of ERK1/2 pathway. J Biol Chem (2005) 1.22
Neurogenic effects of fluoxetine are attenuated in p11 (S100A10) knockout mice. Biol Psychiatry (2010) 1.19
Painful physical symptoms and treatment outcome in major depressive disorder: a STAR*D (Sequenced Treatment Alternatives to Relieve Depression) report. Psychol Med (2009) 1.13
Interferon-gamma promotes differentiation of neural progenitor cells via the JNK pathway. Neurochem Res (2007) 1.07
Transient inactivation of the infralimbic cortex induces antidepressant-like effects in the rat. J Psychopharmacol (2010) 1.02
A role for p11 in the antidepressant action of brain-derived neurotrophic factor. Biol Psychiatry (2010) 0.99
The role of TNF-alpha and its receptors in the production of NGF and GDNF by astrocytes. Brain Res (2006) 0.96
Human cerebral endothelial cells are a potential source for bioactive BDNF. Cytokine (2002) 0.94
Interferon-gamma induces p11 gene and protein expression in human epithelial cells through interferon-gamma-activated sequences in the p11 promoter. J Biol Chem (2003) 0.92
Generation of a conditional allele of the CBP gene in mouse. Genesis (2004) 0.91
Interferon-gamma deficiency modifies the effects of a chronic stressor in mice: Implications for psychological pathology. Brain Behav Immun (2009) 0.86
Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3-specific inhibitor. Nat Med (2003) 12.94
Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci (2005) 9.17
A translational profiling approach for the molecular characterization of CNS cell types. Cell (2008) 8.69
Application of a translational profiling approach for the comparative analysis of CNS cell types. Cell (2008) 7.74
Dichotomous dopaminergic control of striatal synaptic plasticity. Science (2008) 5.47
GSK-3-selective inhibitors derived from Tyrian purple indirubins. Chem Biol (2003) 4.60
Cerebellar neurodegeneration in the absence of microRNAs. J Exp Med (2007) 4.48
Essential role of the histone methyltransferase G9a in cocaine-induced plasticity. Science (2010) 3.97
Regulation of a protein phosphatase cascade allows convergent dopamine and glutamate signals to activate ERK in the striatum. Proc Natl Acad Sci U S A (2004) 3.87
DARPP-32: an integrator of neurotransmission. Annu Rev Pharmacol Toxicol (2004) 3.84
Cocaine-induced dendritic spine formation in D1 and D2 dopamine receptor-containing medium spiny neurons in nucleus accumbens. Proc Natl Acad Sci U S A (2006) 3.68
Alterations in 5-HT1B receptor function by p11 in depression-like states. Science (2006) 3.55
Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Nat Neurosci (2003) 3.25
Intraneuronal Alzheimer abeta42 accumulates in multivesicular bodies and is associated with synaptic pathology. Am J Pathol (2002) 3.23
Pharmacological inhibitors of glycogen synthase kinase 3. Trends Pharmacol Sci (2004) 3.05
Cocaine regulates MEF2 to control synaptic and behavioral plasticity. Neuron (2008) 3.01
IRE1α induces thioredoxin-interacting protein to activate the NLRP3 inflammasome and promote programmed cell death under irremediable ER stress. Cell Metab (2012) 2.80
Gamma-secretase activating protein is a therapeutic target for Alzheimer's disease. Nature (2010) 2.80
Phosphorylation of WAVE1 regulates actin polymerization and dendritic spine morphology. Nature (2006) 2.77
Beta-amyloid accumulation in APP mutant neurons reduces PSD-95 and GluR1 in synapses. Neurobiol Dis (2005) 2.70
Diverse psychotomimetics act through a common signaling pathway. Science (2003) 2.52
Gleevec inhibits beta-amyloid production but not Notch cleavage. Proc Natl Acad Sci U S A (2003) 2.44
Distinct subclasses of medium spiny neurons differentially regulate striatal motor behaviors. Proc Natl Acad Sci U S A (2010) 2.36
Chaperones increase association of tau protein with microtubules. Proc Natl Acad Sci U S A (2003) 2.32
Control of cognition and adaptive behavior by the GLP/G9a epigenetic suppressor complex. Neuron (2009) 2.26
IκB kinase regulates social defeat stress-induced synaptic and behavioral plasticity. J Neurosci (2011) 2.15
Critical involvement of cAMP/DARPP-32 and extracellular signal-regulated protein kinase signaling in L-DOPA-induced dyskinesia. J Neurosci (2007) 2.11
A phosphatase cascade by which rewarding stimuli control nucleosomal response. Nature (2008) 2.10
Reversal of depressed behaviors in mice by p11 gene therapy in the nucleus accumbens. Sci Transl Med (2010) 2.09
Synaptic vesicle mobilization is regulated by distinct synapsin I phosphorylation pathways at different frequencies. Neuron (2003) 2.04
Type 1 phosphatase, a negative regulator of cardiac function. Mol Cell Biol (2002) 1.97
MicroRNA-128 governs neuronal excitability and motor behavior in mice. Science (2013) 1.95
Protein kinase A activates protein phosphatase 2A by phosphorylation of the B56delta subunit. Proc Natl Acad Sci U S A (2007) 1.93
Involvement of DARPP-32 phosphorylation in the stimulant action of caffeine. Nature (2002) 1.91
The neurobiology of dopamine signaling. Arch Neurol (2004) 1.89
Cocaine increases dopamine release by mobilization of a synapsin-dependent reserve pool. J Neurosci (2006) 1.88
Phactrs 1-4: A family of protein phosphatase 1 and actin regulatory proteins. Proc Natl Acad Sci U S A (2004) 1.86
Inhibition of mTOR signaling in Parkinson's disease prevents L-DOPA-induced dyskinesia. Sci Signal (2009) 1.84
Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci (2002) 1.82
Three-dimensional architecture of presynaptic terminal cytomatrix. J Neurosci (2007) 1.82
Roles of heat-shock protein 90 in maintaining and facilitating the neurodegenerative phenotype in tauopathies. Proc Natl Acad Sci U S A (2007) 1.77
Estrogen alters hippocampal dendritic spine shape and enhances synaptic protein immunoreactivity and spatial memory in female mice. Proc Natl Acad Sci U S A (2004) 1.72
Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclin-dependent kinases. J Med Chem (2004) 1.72
Different presynaptic roles of synapsins at excitatory and inhibitory synapses. J Neurosci (2004) 1.72
DARPP-32 mediates the actions of multiple drugs of abuse. AAPS J (2005) 1.66
Impaired recycling of synaptic vesicles after acute perturbation of the presynaptic actin cytoskeleton. Proc Natl Acad Sci U S A (2002) 1.64
Abeta-mediated NMDA receptor endocytosis in Alzheimer's disease involves ubiquitination of the tyrosine phosphatase STEP61. J Neurosci (2010) 1.64
Cell type-specific regulation of DARPP-32 phosphorylation by psychostimulant and antipsychotic drugs. Nat Neurosci (2008) 1.63
Does insulin dysfunction play a role in Alzheimer's disease? Trends Pharmacol Sci (2002) 1.62
Role of p11 in cellular and behavioral effects of 5-HT4 receptor stimulation. J Neurosci (2009) 1.62
Molecular adaptations of striatal spiny projection neurons during levodopa-induced dyskinesia. Proc Natl Acad Sci U S A (2014) 1.59
The Rho-specific GEF Lfc interacts with neurabin and spinophilin to regulate dendritic spine morphology. Neuron (2005) 1.57
L-DOPA activates ERK signaling and phosphorylates histone H3 in the striatonigral medium spiny neurons of hemiparkinsonian mice. J Neurochem (2009) 1.53
Spinophilin blocks arrestin actions in vitro and in vivo at G protein-coupled receptors. Science (2004) 1.52
Colocalization of synapsin and actin during synaptic vesicle recycling. J Cell Biol (2003) 1.50
The amyloid precursor protein and its regulatory protein, FE65, in growth cones and synapses in vitro and in vivo. J Neurosci (2003) 1.50
Estrogen increases the number of spinophilin-immunoreactive spines in the hippocampus of young and aged female rhesus monkeys. J Comp Neurol (2003) 1.49
Distinct roles of PDE4 and PDE10A in the regulation of cAMP/PKA signaling in the striatum. J Neurosci (2008) 1.48
Estrogen replacement increases spinophilin-immunoreactive spine number in the prefrontal cortex of female rhesus monkeys. Cereb Cortex (2004) 1.48
Dopamine enhancement of NMDA currents in dissociated medium-sized striatal neurons: role of D1 receptors and DARPP-32. J Neurophysiol (2002) 1.47
Amyloid-beta oligomers are inefficiently measured by enzyme-linked immunosorbent assay. Ann Neurol (2005) 1.45
Prognostic implication of creatine kinase release after elective percutaneous coronary intervention in the pre-IIb/IIIa antagonist era. Am Heart J (2003) 1.44
Genetic reduction of striatal-enriched tyrosine phosphatase (STEP) reverses cognitive and cellular deficits in an Alzheimer's disease mouse model. Proc Natl Acad Sci U S A (2010) 1.42
Identification of the cortical neurons that mediate antidepressant responses. Cell (2012) 1.42
Presenilin-1 uses phospholipase D1 as a negative regulator of beta-amyloid formation. Proc Natl Acad Sci U S A (2006) 1.41
Argonaute 2 in dopamine 2 receptor-expressing neurons regulates cocaine addiction. J Exp Med (2010) 1.40
FGF acts as a co-transmitter through adenosine A(2A) receptor to regulate synaptic plasticity. Nat Neurosci (2008) 1.36
Spinophilin regulates Ca2+ signalling by binding the N-terminal domain of RGS2 and the third intracellular loop of G-protein-coupled receptors. Nat Cell Biol (2005) 1.36
Presenilin-1 regulates intracellular trafficking and cell surface delivery of beta-amyloid precursor protein. J Biol Chem (2002) 1.34
Regulation of neurotransmitter release by synapsin III. J Neurosci (2002) 1.34
Cdk5 is essential for adult hippocampal neurogenesis. Proc Natl Acad Sci U S A (2008) 1.34
Cholinergic interneurons in the nucleus accumbens regulate depression-like behavior. Proc Natl Acad Sci U S A (2012) 1.33
Regulation of DARPP-32 dephosphorylation at PKA- and Cdk5-sites by NMDA and AMPA receptors: distinct roles of calcineurin and protein phosphatase-2A. J Neurochem (2002) 1.32
Mechanisms of locomotor sensitization to drugs of abuse in a two-injection protocol. Neuropsychopharmacology (2010) 1.32
Roscovitine: a novel regulator of P/Q-type calcium channels and transmitter release in central neurons. J Physiol (2002) 1.32
A small-molecule enhancer of autophagy decreases levels of Abeta and APP-CTF via Atg5-dependent autophagy pathway. FASEB J (2011) 1.31
Multiple actions of spinophilin regulate mu opioid receptor function. Neuron (2008) 1.30
Potentiation of NMDA receptor currents by dopamine D1 receptors in prefrontal cortex. Proc Natl Acad Sci U S A (2004) 1.29
Regulation of phosphorylation of the GluR1 AMPA receptor by dopamine D2 receptors. J Neurochem (2005) 1.29
Spinophilin/neurabin reciprocally regulate signaling intensity by G protein-coupled receptors. EMBO J (2007) 1.29
Methylphenidate-induced dendritic spine formation and DeltaFosB expression in nucleus accumbens. Proc Natl Acad Sci U S A (2009) 1.29
WAVE1 controls neuronal activity-induced mitochondrial distribution in dendritic spines. Proc Natl Acad Sci U S A (2008) 1.28
Involvement of striatal and extrastriatal DARPP-32 in biochemical and behavioral effects of fluoxetine (Prozac). Proc Natl Acad Sci U S A (2002) 1.28
The role of DARPP-32 in the actions of drugs of abuse. Neuropharmacology (2004) 1.27
Glutamate regulation of DARPP-32 phosphorylation in neostriatal neurons involves activation of multiple signaling cascades. Proc Natl Acad Sci U S A (2005) 1.26
A protein kinase A-dependent molecular switch in synapsins regulates neurite outgrowth. Nat Neurosci (2002) 1.25
Phosphorylation of DARPP-32 at Threonine-34 is required for cocaine action. Neuropsychopharmacology (2006) 1.24
A role for LYNX2 in anxiety-related behavior. Proc Natl Acad Sci U S A (2009) 1.23
Phosphorylation of spinophilin modulates its interaction with actin filaments. J Biol Chem (2002) 1.23
Molecular determinants of synapsin targeting to presynaptic terminals. J Neurosci (2004) 1.23
Norbin is an endogenous regulator of metabotropic glutamate receptor 5 signaling. Science (2009) 1.22
The B''/PR72 subunit mediates Ca2+-dependent dephosphorylation of DARPP-32 by protein phosphatase 2A. Proc Natl Acad Sci U S A (2007) 1.21
Mechanism of regulation of casein kinase I activity by group I metabotropic glutamate receptors. J Biol Chem (2002) 1.21
Increased activity of cyclin-dependent kinase 5 leads to attenuation of cocaine-mediated dopamine signaling. Proc Natl Acad Sci U S A (2005) 1.21
Quantitative analysis of protein phosphorylation in mouse brain by hypothesis-driven multistage mass spectrometry. Anal Chem (2005) 1.20
Distinct roles of dopamine D2L and D2S receptor isoforms in the regulation of protein phosphorylation at presynaptic and postsynaptic sites. Proc Natl Acad Sci U S A (2003) 1.20
Structural domains involved in the regulation of transmitter release by synapsins. J Neurosci (2005) 1.19